TriNetX’s research network includes member companies like Allergan, Pfizer, and Sanofi, alongside multiple academic research institutes. Most recently, Tufts entered the network in April 2018 followed by University Hospitals in January 2019.
Houston Methodist, an academic and medical center, encompasses a translational research institute, and eight hospitals serving more than 1.3m patients. The hospital system also holds 1,960 credentialed researchers and 1,261 clinical protocols.
Edward Jones, president and CEO of Houston Methodist Research Institute, said in a press release, “this membership allows us to broaden our participation in clinical trials for novel therapeutics that represent the prospect of hope to our patients.”
TriNetX’s research network currently spans 16 countries and thousands of clinical research sites representing over 300m patients.
Houston Methodist Hospital will gain access to the networks, which connects clinical researchers to patient populations in real-time. Additionally, it will have access to TriNetX’s analytic self-service offering added February 21, 2019 to simplify the analysis of real world data (RWD).
Houston Methodist did not respond to our request for comment.